JBCPL gets trademark assignment of heart failure drug Azmarda from Novartis
JB Chemicals and Pharmaceuticals (JBCPL) has recently announced that the company has approved the assignment of trademark for Azmarda indicated for heart failure patients with reduced ejection fraction (HFrEF) from Novartis AG, Switzerland for India.Azmarda is a brand of sacubitril/valsartan, the first-in-class angiotensin receptor neprilysin inhibitor (ARNI) presently approved for the...
JB Chemicals and Pharmaceuticals (JBCPL) has recently announced that the company has approved the assignment of trademark for Azmarda indicated for heart failure patients with reduced ejection fraction (HFrEF) from Novartis AG, Switzerland for India.
Azmarda is a brand of sacubitril/valsartan, the first-in-class angiotensin receptor neprilysin inhibitor (ARNI) presently approved for the treatment of heart failure with reduced ejection fraction (HFrEF).
For more information, check out the full story on the link below:
JBCPL Gets Trademark Assignment Of HF Drug Azmarda From Novartis For Rs 246 Crores
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd